posts 
Fierce Pharma
MAY 9, 2024
s Keytruda already boasts a pair of approvals to treat certain forms of endometrial cancer, a recent effort to prove the PD-1 inhibitor’s worth as a post-surgery add-on therap | While Merck & Co.’s While Merck & Co.’s
Fierce Pharma
MAY 7, 2024
While cystic fibrosis has long been Vertex Pharmaceuticals’ bread and butter, the company has been eager to diversify its revenue base in recent years. | As of mid-April, Vertex said it had collected 5 patients' cells for eventual treatment with sickle cell disease therapy Casgevy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MAY 10, 2024
While some biopharma contract manufacturers have been able to weather a tough business environment in recent months, many others continue to struggle against financing headwinds affecting the great | AGC Biologics, which employs more than 2,500 workers worldwide, has “had to reduce positions at our Seattle and Colorado sites and global functional areas,” (..)
Fierce Pharma
OCTOBER 22, 2023
As Novartis aims to move its radiotherapy Pluvicto into an earlier treatment setting in prostate cancer, it has posted a mixed bag of trial data that cast a cloud of uncertainty over its regulatory path forward. Novartis has high hopes for its radiotherapy Pluvicto. |
Advertiser: ZoomInfo
Businesses are laying off workers, shutting their doors (some permanently), and struggling to react to the radical destruction that coronavirus (COVID-19) is doing to our society and communities. Most have already sustained massive damage, and we still have yet to see the scope of this global pandemic.
MedCity News
JANUARY 17, 2024
CPSI sold American HealthTech — its subsidiary that provides an EHR platform for the post-acute care market — to post-acute health IT vendor PointClickCare. American HealthTech’s customers have already begun transitioning to PointClickCare’s platform.
Fierce Pharma
AUGUST 16, 2023
But a surge in post-pandemic collections—and an $11.7B With plasma collection as its stock-in-trade, the struggles of | With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. acquisition of Swiss blood specialist Vifor—has rekindled the growth of Australia’s largest biotech.
Expert insights. Personalized for you.
275 
Let's personalize your content